Alkermes Plc Hits New 52-Week High of $45.76, Up 85.7%

Alkermes Plc has reached a significant milestone by hitting a new 52-week high of USD 45.76 on June 11, 2026. This achievement marks a remarkable performance over the past year, with the stock appreciating by 85.7%, significantly outpacing the S&P 500's growth of 22.78% during the same period. As a small-cap company in the Pharmaceuticals & Biotechnology sector, Alkermes boasts a market capitalization of USD 5,008 million. The company's price-to-earnings (P/E) ratio stands at 21.00, reflecting its valuation relative to earnings. Additionally, Alkermes has a return on equity of 13.28%, indicating effective management of shareholder equity. Despite the absence of a dividend yield, the stock's price-to-book ratio is 2.75, suggesting a premium valuation compared to its book value. The company's debt-to-equity ratio of -0.72 indicates a strong financial position, with no reliance on debt for financing. Overall, Alkermes Plc's recent performance underscores its robust standing in the market.